


<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>PC31759A/US</b>  U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/539856</b>
INTERNATIONAL APPLICATION NO. <b>PCT/US2003/040181</b>	INTERNATIONAL FILING DATE <b>17 December 2003 (17.12.2003)</b>	PRIORITY DATE CLAIMED <b>18 December 2002 (18.12.2002)</b>
TITLE OF INVENTION <b>Method of Using a Cox-2 Inhibitor and a Topoisomerase II Inhibitor as a Combination Therapy in the Treatment of Neoplasia</b>		
APPLICANT(S) FOR DO/EO/US <b>MASFERRER, Jaime L.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).  Items 11 to 20 below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: (w/replacement sheets); Return Receipt Postcard; Express Mail Label EV 726255863 US.		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>10/539856</b>		INTERNATIONAL APPLICATION NO. PCT/US2003/040181		ATTORNEY'S DOCKET NUMBER PC31759A/US	
The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21. <input checked="" type="checkbox"/> Basic national fee..... \$300				\$ 300.00	
22. <input checked="" type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)..... \$100 All other situations..... \$200				\$ 200.00	
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100 International Search Report prepared and provided to the Office..... \$400 All other situations..... \$500				\$ 400.00	
TOTAL OF 21, 22 and 23 =				\$ 900.00	
<input checked="" type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
236 - 100 =	136 /50 =	3	x \$250	\$ 750.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	9 - 20 =		x \$ 50	\$	
Independent claims	2 - 3 =		x \$200	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 1,650.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				0.00	
SUBTOTAL =				\$ 1,650.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1,650.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 40.00	
TOTAL FEES ENCLOSED =				\$ 1,690.00	
				Amount to be refunded:	\$
				Amount to be charged:	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,690.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>08-0750</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Christian Smolizza (Reg. No. 46,319)					
Pfizer Inc.					
150 East 42nd Street					
150/549S-IP Legal					
New York, NY 10017					
USA					
				 SIGNATURE Lydia N. Nenow NAME 52,530 REGISTRATION NUMBER	

539856

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jaime L. Masferrer  
Serial No: TBA (§371 Application Based on PCT/US2003/040181)  
Filed: June 16, 2005  
Title: Method of Using a Cox-2 Inhibitor and a Topoisomerase II Inhibitor as a Combination Therapy in the Treatment of Neoplasia  
Group Art Unit: TBA  
Examiner: TBA  
Attorney Ref: PC31759A/US  
HDP Ref: 6794F-000032/NPN

June 17, 2005

**TRANSMITTAL LETTER**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir/Madam:

The above-referenced patent application is a U.S. national phase application filed under 35 U.S.C. §371 based on International Patent Application No. PCT/US2003/040181 (filed December 17, 2003). Applicant respectfully submits the following:

1. Transmittal Letter to the United States Designated/Elected Office Concerning a Submission under 35 U.S.C. §371 (2 pages) (in duplicate).
2. Check for \$1,690.00 to cover the basic national fee, examination fee, search fee, extra sheets fee, and assignment recordation fee.
3. Executed Declaration and Power of Attorney (3 pages).
4. Assignment (2 pages).
5. Assignment Recordation Cover Sheet (1 page).
6. PCT Publication No. WO 2004/058302 A1 (239 pages).
7. International Search Report (3 pages).
8. International Preliminary Examination Report (with 4 replacement sheets) (8 pages).
9. Preliminary Amendment (9 pages).

U.S. Patent Application No. TBA  
(§371 Application Based on PCT/US2003/040181)  
Transmittal Letter  
June 17, 2005

10. Return Receipt Postcard.

Applicant has enclosed a check to cover the fees for this application (*i.e.*, basic national fee; examination fee; search fee; extra sheets fee; and assignment recordation fee). Applicant does not believe that any additional fees are due in connection with this filing. If, however, Applicant owes any additional fee(s) in connection with this filing, the Commissioner is hereby authorized to charge those fee(s) to Deposit Account No. **08-0750**.

Applicant requests that all correspondence for this application be sent to:

Christian Smolizza  
Pfizer, Inc  
150 East 42nd Street  
150/5/49S-IP/Legal  
New York, New York 10017  
(212) 733-9094 (tel)  
(212) 573-1939 (fax)

Applicant also requests that the Examiner call Christian Smolizza if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



Lydia N. Nenow, PTO Reg. No. 52,530  
Harness, Dickey & Pierce, PLC  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

U.S. Patent Application No. 77A  
(§371 Application Based on PCT/US2003/040181)  
Transmittal Letter  
June 17, 2005

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8**

I certify that this correspondence is being deposited with the U.S. Postal Service on **June 17, 2005** with sufficient postage as first class mail (including Express Mail per MPEP §512), and addressed to **Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



---

Lydia N. Nenow, PTO Reg. No. 52,530

LNN/LVE